From WisPolitics.com/WisBusiness.com …
— The Wisconsin Hospital Association is touting an analysis from Becker’s Hospital Review that shows high levels of patient satisfaction with five-star hospitals in the state.
The publication’s recent analysis focused on Hospital Consumer Assessment of Healthcare Providers and Systems scores. It found Wisconsin was the No. 1 state among those with 100 or more hospitals for the share of five-star rated hospitals that patients “definitely recommend,” with 23%.
That’s well above the other peer states in the top five, which include: North Carolina, 15%; Pennsylvania, 14%; and Iowa and Michigan, 13% each. Among all states, Wisconsin was ranked third behind Maine and Utah, WHA notes.
The group also says 96% of patients in Wisconsin would “probably” or “definitely” recommend their local hospital to friends or family, based on the latest HCAHPS scores.
WHA President and CEO Eric Borgerding says some criticize hospital quality in the state “to advance political agendas, but data directly from patient satisfaction scores tells a much different story.
“What is of great concern to patients, workers and families all across the state is the frustrating complexity, red tape, care denials, co-pays, deductibles and other surprise costs that the mega insurance companies, third party administrators and other health care middlemen continue heaping onto our healthcare care system while avoiding much needed scrutiny,” he argued.
See the analysis and find WHA’s release below.
— Exact Sciences is publicizing new results for its Oncodetect cancer test, which demonstrate its “strong performance” in detecting disease and predicting recurrence.
That’s according to Brian Baranick, general manager of precision oncology at the Madison-based diagnostics company.
“We’re thrilled to bring our MRD solution to the rapidly growing molecular residual disease market, helping more patients get access to critical, high-quality testing,” Baranick said in a statement.
Molecular residual disease describes tumor DNA leftover following cancer treatment, an overview from the company shows. This ctDNA, or circulating tumor DNA, can indicate the presence of cancer in the body. The Oncodetect test aims to identify changes in DNA taken from a patient’s tumor, informing cancer therapy decisions and monitoring potential cancer recurrence.
Exact Sciences says 3 million people in the United States could benefit from MRD testing, based on an internal estimate of the addressable patient population. Oncodetect is set to launch in the second quarter of this year.
Yesterday’s release shows the Alpha-CORRECT study found the Oncodetect study had 78% sensitivity post-surgery and 91% sensitivity during the surveillance monitoring period. These findings indicate the test can successfully identify residual disease, the company says.
Full findings from that study of patients with colon cancer will be published later this week, according to the release.
Meanwhile, Exact Sciences is also touting results from the Beta-CORRECT study, which show a “significant association” between positive test results and recurrence for patients with stage III colon cancer. The company notes these findings also “extend Oncodetect’s prognostic value” to patients with stages II and IV colon cancer and rectal cancer.
Dr. Takayuki Yoshino, deputy director at the National Cancer Center Hospital East in Japan, says Exact Sciences’ test “represents an exciting development” in the field of cancer monitoring.
“There is a critical need to better understand and monitor for residual cancer following surgery … I am pleased to partner with Exact Sciences, encouraged by the emerging data from the Beta-CORRECT study, and look forward to sharing further insights in the coming months,” Yoshino said in a statement.
See the release below.
Top Stories
– National Institutes of Health cancel scientific meetings after Trump directives
– Trump to address anti-abortion March for Life by video, Vance in person
– As States Diverge on Immigration, Hospitals Say They Won’t Turn Patients Away
– GOP senators introduce bill to ban taxpayer funding for abortions
– New Research Finds Potential Alternative to Abortion Pill Mifepristone
– Purdue Pharma, Sacklers reach $7.4 bln national opioid settlement
– ADHD linked to shorter life expectancy: Research
Press Releases
